Compliance Commitment

Please read these terms and conditions of use carefully before using this Novo Nordisk Inc site. By using a Novo Nordisk Inc. site and any third-party site that is linked to a Novo Nordisk Inc. site you signify your agreement to these terms. Novo Nordisk Inc. reserves the right to change, modify, add, or remove portions of these terms. Please check these terms periodically for changes. Your continued use of a Novo Nordisk Inc. site following the posting of changes to these terms will mean that you accept those changes.

Novo Nordisk Inc. sites are produced, owned and operated by Novo Nordisk Inc. and its parent company, Novo Nordisk A/S, and are protected by copyright and trademark laws. All materials contained in any Novo Nordisk Inc. site are the copyright property of Novo Nordisk Inc. or its parent company, Novo Nordisk A/S, or its subsidiaries or affiliate companies and/or third-party licensors. Novo Nordisk Inc. is one subsidiary of Novo Nordisk A/S among other companies in the Novo Nordisk group of companies. Neither these affiliate companies nor the parent company can be held responsible, either directly or indirectly, for any harm, damage or inconvenience that might arise from the use of this site, or from your reliance on any information or materials provided on this site, or any third-party site linked to or from this site.

All trademarks, servicemarks and tradenames are proprietary to Novo Nordisk Inc., its parent company or its affiliates. No material from any Novo Nordisk Inc. site owned, operated, licensed, or controlled by us or our affiliates or parent company may be copied reproduced, republished, uploaded, posted, transmitted, or distributed, in any way, except that you may download one copy of the materials or forward pages from this site, you must (i) not alter any copyrights or other proprietary notices, (ii) make no modifications to the materials, (iii) you may not use the materials in a manner that suggests an association with any of our products, services or brands, and (iv) you may not download quantities of materials to a database that can be used to avoid future downloads from any Novo Nordisk Inc. site. For purposes of these terms, the use of any such material on any other website or computer environment is prohibited.

Novo Nordisk Safety Reporting Requirements Policy

Obligations and responsibilities of the Sponsor-Investigator related to safety reporting

When reporting Adverse Events the following parameters must be recorded:

• Study name
• Patient identification (e.g. subject number, initials, sex, age)
• Event (preferably a diagnosis)
• Drug (e.g. Norditropin Simplex^®)
• Reporter identification (e.g. name, or initials)
• Causality
• Outcome

a) Reporting to Health Authorities

The Sponsor-Investigator shall be responsible for all required periodic updates to health authorities and expedited reporting of Adverse Events occurring during the performance of the study, in accordance with local regulations and the agreed protocol.

The approving Health Authority may:

• Have special requests beyond Serious Unexpected Suspected Adverse Reaction (SUSAR) reporting
• Allow not to unblind and expedite specific SUSARs

Sponsor-investigators have obligations for reporting of relevant serious adverse events (SAE) information to the Competent Authority and Independent Ethics Committee/ Institutional Review Boards based upon federal regulations and Local/IRB policies.

b) Reporting to Novo Nordisk

For all IIS studies, when the Principal Investigator is aware that the study subject has been exposed to a Novo Nordisk product (including placebo, if supplied by Novo Nordisk), the following information must be reported in English to Novo Nordisk:

• SADRs include all SAEs which are probably or possibly related to any Novo Nordisk product.
• Indicate on any SADR whether it has been submitted to local health authorities.
• In addition to SADRs, any other events that have been submitted to the health authorities according to local regulatory requirements in the participating country shall be sent to Novo Nordisk at the time of submission to health authorities.

• Pregnancies include pregnancies that occur in patients receiving Novo Nordisk products or pregnancies that occur in trial subject's partners whose foetus or baby develops an adverse event considered to be related to the trial product.
• SADRs and pregnancy reports are to be reported to Novo Nordisk via the approved Local Regulatory form (i.e FDA Medwatch form, CIOMS, etc.) An Event Fax Cover sheet will be provided by Novo Nordisk.
• Reportable Events subject to this provision are those that occur from the first dose of Novo Nordisk product, through the specified time period described in the protocol.
• The Principal Investigator shall provide further information about safety related events to NN, if the Principal Investigator receives specific requests from Novo Nordisk.
• The Principal Investigator also agrees to assist Novo Nordisk with follow-up of only SAE Reports.

• The Sponsor-Investigator agrees to the terms of Novo Nordisk safety reporting policy for IIS Studies.
• The Sponsor-Investigator agrees to comply with Adverse Event reporting required by federal regulations and Local/IRB policies.
• Should Novo Nordisk agree to providing funding and/or drug for my IIS, I agree to Register the Trial Information, Status and results under applicable rules on clinicaltrials.gov and other Relevant sites.
• The protocol describes the ethical principles under which the study will be conducted (e.g. ICH, GCP), the manner in which the study will be reviewed by IRB/IACUC, and the procedures for obtaining informed consent.

I certify that the statements made in this request application are true, complete and accurate to the best of my knowledge.

By clicking here, you have read, understand and agree to all of the above terms and conditions.